U.S. Markets for Neurosurgical and Neurointerventional Products Report
|出版日||ページ情報||英文 116 Pages
|米国の脳神経外科および神経インターベンション外科製品市場 U.S. Markets for Neurosurgical and Neurointerventional Products Report|
|出版日: 2014年09月01日||ページ情報: 英文 116 Pages||
This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Neurosurgical and Neurointerventional Products Market. Specifically, this report covers neurosurgical, neurointerventional and image-guided surgical navigation and brain radiotherapy systems used for the treatment of several acute and chronic disorders such as benign and malignant neoplasms, hemorrhagic and ischemic stroke, hydrocephalus, intracranial aneurysms and arterio-venous malformations, and epilepsy.
Neurosurgery encompasses multiplicity of surgical procedures involving various tissues of the central nervous system, and include surgical interventions performed on the brain and skull, spinal cord and spinal canal, cranial and peripheral nerves, as well as the sympathetic nerves. This report focuses on procedures and products used in traditional “open” neurosurgical interventions, or those requiring direct intracranial access, including neurosurgical instruments used for gaining access to, cutting and removing diseased tissue, electrosurgical devices used for tissue ablation and vessel coagulation in the treatment of hemorrhage, and ultrasonic aspiration systems employed in fragmentation and removal of tissue.
Neurointerventional radiology employs a variety of standard and application-specific transcatheter tools and techniques for treatment of cerebrovascular pathologies [such as aneurysms, arteriovenous malformations (AVMs), acute and chronic thromboembolic and atherosclerotic occlusions] that prompt clinically significant distortions of cerebral blood flow and carry a high risk of catastrophic breakdowns of cerebrovascular circulation manifested by hemorrhagic or ischemic stroke. This report provides a market analysis of transcatheter embolization systems for cerebral aneurysms and AVMs, adjuvant embolic coil containment stenting (used for management of wide-neck aneurysms), novel specialty stent/graft-based flow redirection devices for large wide-neck aneurysms, distally protected carotid artery stenting systems (for treatment of high-grade carotid stenosis), intracranial stents HDE-approved for management of symptomatic intracerebral stenosis, and mechanical cerebral thrombectomy systems targeting selected patient subsets with acute ischemic stroke.
The third area analyzed in this report includes image-guided neurosurgical navigation systems used for intraoperative guidance of surgical instruments in complex intracranial and other surgical procedures, and external beam radiotherapy (EBRT) systems (e.g., Gamma Knife and linear accelerator/LINAC platforms) employed in adjuvant and primary treatment of various oncological and other pathologies characterized by abnormal brain lesions.
In 2013, the total combined U.S. neurosurgical and neurointerventional products market was valued at approximately $1.5 billion. Over the forecast period covered by this report, total sales are expected to increase at a compound annual rate of 4.2%, reaching more than $1.8 billion in the year 2018.
Of the three core markets, neurointerventional systems are expected to exhibit the highest growth, with U.S. revenues forecast to increase at a moderate, single-digit (yet comparatively healthy) compound annual rate of 6.5% over the next 5 years. Gains will be supported by anticipated strong advances in distally protected carotid stenting (CAS) and cerebral thrombectomy systems revenues. In comparison, the second largest segment-the neurosurgical instrument/devices market-is expected to increase at a lower compound annual rate of 2.6%. Modest advances in the technologically and a clinically mature neurosurgical instrument/device group will be driven by organic epidemiology trends, augmented by modest device price inflation. The smallest of the three core markets discussed in this report-image-guided neurosurgical navigation and radiotherapy systems-is forecast to increase at a low yet steady compound annual rate of 1.9%.